A Study of the Safety and Effectiveness of Experimental Perampanel For Partial Onset Seizures

Enter your info and the study team will contact you soon!
Your data is securely stored and only shared with the research team
Logo Image
"Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!"
Age: 12 years or older
Gender:
Any
Healthy Volunteers: No
Keywords: seizures, Partial Onset Seizures, Secondarily Generalized Seizures, Primary Generalized Tonic-Clonic Seizures
Type: Drug study, Phase 4
Target:
5 Participants
Investigator:
Description
The purpose of the study is to investigate the study drug perampanel. The study team wants to learn if perampanel can be used alone without the need for combining with other antiepileptic medicines. It will also be studied as the first addition to existing medicine if only one seizure medication is being taken.

Perampanel (E2007) is an experimental drug. This means that the drug being tested in this study and has not been approved by the FDA as an anti-epileptic medication.
This study requires

The study team will make sure you qualify to take part in the study. Qualified participants will receive detailed information about the study. This may include a list of study-related tests and procedures.

Who can participate

Inclusion criteria:

  • Participants will be male or female and no younger than 12 years of age.
  • Participants must have a diagnosis of epilepsy with partial-onset seizures (POS) (with or without secondarily generalized seizures [SG]) or with primary generalized tonic clonic seizures (PGTC) according to the International League Against Epilepsy's (ILAE) Classification of Epileptic Seizures (1981).
  • Participants who receive perampanel as a first adjunctive therapy must currently have been treated with stable doses of monotherapy for 8 weeks prior to Visit 2 (Week 0), have not previously received adjunctive anti-epileptic drug (AED) treatment, and must, in the investigator's judgement, be in need of initial adjunctive therapy after failure to control seizures with AED monotherapy, at the optimal dose and duration.
  • Participants who receive perampanel as monotherapy, who were newly diagnosed (treatment naïve), must have experienced 2 or more well documented seizures within the past year, with at least 24 hours between these seizures.
  • Participants who are currently receiving monotherapy treatment may receive perampanel as monotherapy if, in the investigator's judgment, the participant may benefit from a change in monotherapy treatment. Participants must not have previously received adjunctive AED treatment.
  • If antidepressants or antianxiety drugs are used, participants must be on a stable dose regimen of these drugs during the 8 weeks before Visit 2 (Week 0).

Exclusion criteria:

  • Participants should not have previously received or currently be receiving perampanel.
  • Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta human chorionic gonadotropin [β-hCG] or hCG test with a minimum sensitivity of 25 International Units per liter [IU/L] or equivalent units of β-hCG or hCG); a separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.
  • Females of childbearing potential who:
  • Within 28 days before study entry, did not use a highly effective method of contraception, which includes any of the following:
  • Total abstinence (if it is their preferred and usual lifestyle)
  • An intrauterine device or intrauterine hormone-releasing system
  • An oral contraceptive (with additional barrier method if using contraceptive containing levogesterol); participant must be on a stable dose of the same oral contraceptive product for at least 28 days before dosing and throughout the study and for 28 days after study drug discontinuation
  • Have a vasectomized partner with confirmed azoospermia
  • Do not agree to use a highly effective method of contraception (as described above) throughout the entire study period and for 28 days after study drug discontinuation For sites outside of the European Union, it is permissible that if a highly effective method of contraception is not appropriate or acceptable to the participant, then the participant must agree to use a medically acceptable method of contraception, ie, double barrier methods of contraception such as condom plus diaphragm or cervical/vault cap with spermicide. NOTE: All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing).
  • Presence of or previous history of Lennox-Gastaut syndrome
  • Presence of non-motor simple partial seizures only
  • A history of status epilepticus within 1 year before Screening Visit (Visit 1)
  • Participants on antipsychotics or who have psychotic disorder(s) or unstable recurrent affective disorder(s) with a history of attempted suicide within 1 year before Screening Visit (Visit 1)
  • Presence of a progressive central nervous system (CNS) disease, including degenerative CNS diseases and progressive tumors
  • Concomitant use of barbiturates (except for seizure control indication and premedication for electroencephalogram) and benzodiazepines (except for seizure control indication) within 8 weeks prior to Visit 2 (Week 0)
  • Use of intermittent rescue benzodiazepines (ie, 1 to 2 doses over a 24-hour period is considered a one time rescue) 2 or more times in the 8-week period prior to Visit 2 (Week 0)
  • Severe renal insufficiency (defined by estimated glomerular filtration rate of < 30 milliliters per minute [mL/min]) or participants who receive hemodialysis
  • Evidence of clinically significant disease (eg, cardiac, respiratory, gastrointestinal, renal disease, hepatic disease) that in the opinion of the investigator(s) could affect the participant's safety or study conduct NOTE: Stable elevation of liver enzymes, alanine aminotransferase and aspartate aminotransferase due to concomitant medication(s) will be allowed if they are less than 3 times the upper limits of normal.
  • Hypersensitivity to perampanel or any excipients
  • Participants with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption
  • Participants who are participating in other interventional clinical trial
  • Participant who are judged to have inadequate cognitive ability for participation in the study (intelligence quotient < 80 or investigator judgment)
  • Any suicidal ideation with intent with or without a plan, at the time of or within 6 months of screening, as indicated by answering "Yes" to questions 4 and 5 on the Suicidal Ideation section of the Columbia Suicide Severity Rating Scale (C-SSRS)
  • Any lifetime suicidal behavior based on the C-SSRS
Benefits and risks of participating
BENEFITS:

We cannot promise any benefits to you as a result of taking part in this research study.


RISKS:

The study doctor will discuss the risks associated with taking part in this research study.
Compensation
If you agree to take part in this research study, we will compensate you $50 for each study visit you complete.
Resources
Schedule
Study duration and period
We expect that you will be in this research study for about a little over 1 year (56 weeks or 12.5 months).
Recruitment period
From Nov. 14, 2018
Location
UC Davis Medical Center
2315 Stockton Boulevard
Sacramento, CA 95817
Contact
Kelly Wallace
Research Topic
Conditions:
  • Partial Onset Seizures
  • Secondarily Generalized Seizures
  • Primary Generalized Tonic-Clonic Seizures